secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001193125-22-011228
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Therapeutics appoints John Maraganore, Ph.D. to Board of Directors
-------------------------------------------------------------------------

- John Maraganore, Ph.D. appointed to Kymera's Board effective January 17, 2022.
- Dr. Maraganore will serve as a Class III director with term expiring at 2023 annual meeting.
- Board determined Maraganore is independent under Nasdaq listing standards; committee compositions unchanged.
- As non-employee director, he will receive cash and equity per Company's Non-Employee Director Compensation Policy.
- No transactions requiring disclosure per Item 404(a) and no arrangements with others for selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522011228/0001193125-22-011228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522011228/d297242d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-011228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer